Latest Period
Q1 2026
Security Snapshot
Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM) Institutional Ownership
CUSIP: 21217B100
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
90
Shares (Excl. Options)
30,555,198
Price
$13.06
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Common Stock, $0.001 par value per share
- Symbol
- CTNM on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 30,555,198
- Total 13F value
- $398,924,273
- Portfolio coverage rank
- 0%
- Share change
- +356,838
- Value change
- +$6,773,778
- Number of holders
- 90
- Shares outstanding
- 32,400,300
- SEC-reported price per share
- $13.06
- Insider filing price
- $13.06
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CTNM - Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share is tracked under CUSIP 21217B100.
- 90 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 80 to 90 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $338,263,936 to $398,924,273.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 90 institutions filings for Q1 2026.
Security key
21217B100
Latest holder period
Q1 2026
13F holders
90
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
CTNM full holder history
Contineum Therapeutics, Inc. SEC filings
Contineum Therapeutics, Inc. company facts
Contineum Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 21217B100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
CTNM
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 7.9% | $27,991,830 | 2,448,979 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 7.4% | -2.5% | $31,575,462 | +$1,370,294 | 2,417,723 | +4.5% | Balyasny Asset Management L.P. | 31 Mar 2026 |
| FRANKLIN RESOURCES INC | 6.2% | -19% | $21,479,661 | +$2,558,072 | 1,879,367 | +14% | Franklin Resources, Inc. | 31 Dec 2025 |
| MILLENNIUM MANAGEMENT LLC | 5.1% | $21,658,701 | 1,658,349 | Millennium Management LLC | 13 Apr 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 4% | -46% | $16,925,917 | -$11,541,109 | 1,296,012 | -41% | RA Capital Management, L.P. | 31 Mar 2026 |
| SECTORAL ASSET MANAGEMENT INC | 5% | $4,297,553 | 950,786 | Jerome G. Pfund | 31 Dec 2024 | |||
| PERCEPTIVE ADVISORS LLC | 3.2% | -54% | $2,776,959 | -$2,944,799 | 699,486 | -51% | Perceptive Advisors LLC | 30 Jun 2025 |
As of 31 Mar 2026, 90 institutional investors reported holding 30,555,198 shares of Contineum Therapeutics, Inc. - Class A Common Stock, $0.001 par value per share (CTNM). This represents 94% of the company’s total 32,400,300 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
82%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 8.8% | 2,841,334 | 0% | 1% | $37,107,822 |
| JANUS HENDERSON GROUP PLC | 8.4% | 2,734,836 | +12% | 0.02% | $35,593,891 |
| JOHNSON & JOHNSON | 6.1% | 1,979,173 | 0% | 4% | $25,847,999 |
| FRANKLIN RESOURCES INC | 5.7% | 1,839,227 | -2.1% | 0.01% | $24,020,305 |
| Balyasny Asset Management L.P. | 5.2% | 1,685,635 | -8.5% | 0.04% | $22,014,393 |
| MILLENNIUM MANAGEMENT LLC | 4.7% | 1,535,449 | +85% | 0.02% | $20,052,964 |
| BAKER BROS. ADVISORS LP | 4.4% | 1,420,838 | 0% | 0.11% | $18,556,144 |
| RA CAPITAL MANAGEMENT, L.P. | 4% | 1,296,012 | -41% | 0.18% | $16,925,917 |
| PERCEPTIVE ADVISORS LLC | 3.9% | 1,255,592 | -14% | 0.32% | $16,398,032 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 1,214,173 | 0% | 0% | $15,857,099 |
| FMR LLC | 2.5% | 814,871 | 0% | 0% | $10,642,215 |
| Ikarian Capital, LLC | 2.5% | 807,874 | +186% | 1.5% | $10,550,835 |
| GREAT POINT PARTNERS LLC | 2.5% | 800,198 | +0.02% | 2.6% | $10,450,586 |
| Longaeva Partners L.P. | 2.3% | 732,088 | +56% | 0.46% | $9,561,069 |
| SECTORAL ASSET MANAGEMENT INC | 2.2% | 727,587 | -9.1% | 7.9% | $9,502,286 |
| HHLR ADVISORS, LTD. | 2.1% | 669,337 | 0% | 0.52% | $8,741,541 |
| BlackRock, Inc. | 2.1% | 669,123 | +25% | 0% | $8,738,746 |
| RED TREE MANAGEMENT, LLC | 2% | 638,158 | 0% | 7.5% | $8,334,343 |
| Versant Venture Management, LLC | 1.7% | 542,628 | 0% | 5% | $7,086,722 |
| Jones Hill Capital LP | 1.6% | 513,053 | 0% | 1.4% | $6,700,472 |
| Boxer Capital Management, LLC | 1.5% | 494,000 | 0% | 0.85% | $6,451,640 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.1% | 371,636 | +40% | 0.01% | $4,853,566 |
| CITADEL ADVISORS LLC | 1.1% | 350,200 | 0% | $4,573,612 | |
| GOLDMAN SACHS GROUP INC | 0.95% | 307,108 | +191% | 0% | $4,010,830 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.93% | 301,729 | -1.9% | 0.46% | $3,940,581 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 30,555,198 | $398,924,273 | +$6,773,778 | $13.06 | 90 |
| 2025 Q4 | 29,602,152 | $338,263,936 | +$137,435,356 | $11.43 | 80 |
| 2025 Q3 | 17,478,081 | $205,365,503 | +$48,626,432 | $11.75 | 61 |
| 2025 Q2 | 13,856,430 | $55,287,652 | -$6,405,461 | $3.97 | 68 |
| 2025 Q1 | 15,121,377 | $105,552,026 | -$10,223,173 | $6.98 | 62 |
| 2024 Q4 | 15,761,089 | $230,901,673 | +$20,179,605 | $14.65 | 60 |
| 2024 Q3 | 13,713,806 | $258,404,333 | +$11,041,962 | $19.14 | 52 |
| 2024 Q2 | 13,016,510 | $229,220,181 | +$229,145,565 | $17.61 | 49 |